Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists
December 20, 2023 09:00 ET
|
Scilex Holding Company
ZTlido® is the most prescribed non-opioid, branded pain treatment prescribed by pain specialists.1Total ZTlido® NRx (New Drug Prescription) market share for the non-opioid branded pain treatment...
Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid Colchicine Formulation Designed for Precision Dosing
December 19, 2023 09:00 ET
|
Scilex Holding Company
Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Gout is a painful arthritic disorder affecting...
Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB® in most of their stores throughout the U.S.
December 15, 2023 09:00 ET
|
Scilex Holding Company
National leading pharmacy chain to stock ELYXYB® in most of their stores throughout the U.S.Previously, Scilex Holding Company announced pharmacy initiative to stock ELYXYB® for the other leading...
Scilex Holding Company Announces Expanded Access to ELYXYB® By the Execution of First ELYXYB® Insurance Coverage Agreement with One of the Top Three National PBMs (Pharmacy Benefit Manager) for its Medicare Population
December 12, 2023 09:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Scilex Holding Company announces that ZTlido® (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State
December 06, 2023 09:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee
December 04, 2023 09:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended November 2023, And Year-To-Date Through November 30, 2023, Based On Currently Available Information
December 01, 2023 09:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Scilex Holding Company announces successful FDA audit of enhanced ZTlido® manufacturing facility in Japan
November 30, 2023 09:00 ET
|
Scilex Holding Company
Enhanced 250kg manufacturing facility assures increased capacity to meet rapidly growing ZTlido® demand.Two new patents previously announced covering ZTlido® in the U.S. ensures proprietary protection...
Scilex Holding Company announces pharmacy initiative to stock ELYXYB® in over 500 stores for a leading pharmacy chain in the U.S.
November 28, 2023 09:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024
November 27, 2023 09:00 ET
|
Scilex Holding Company
Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Gout is a painful arthritic disorder affecting...